Eric Lefebvre - Jun 18, 2021 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
Chief Medical Officer
Signature
/s/ Mike Ouimette, attorney-in-fact
Stock symbol
PLRX
Transactions as of
Jun 18, 2021
Transactions value $
-$360,821
Form type
4
Date filed
6/22/2021, 07:52 PM
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Sale -$250K -8.75K -5.85% $28.62 141K Jun 18, 2021 Direct F1, F2
transaction PLRX Common Stock Sale -$110K -3.73K -2.65% $29.43 137K Jun 18, 2021 Direct F1, F3
transaction PLRX Common Stock Sale -$665 -22 -0.02% $30.23 137K Jun 18, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.2000 to $29.1900, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.2000 to $29.8500, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.